Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.

@article{Kim2006EffectOC,
  title={Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.},
  author={Kyoung-ah Kim and P Park and Ock-Je Lee and S Choi and Bon Hong Min and Kyung-ho Shin and Boe-Gwun Chun and Jae-Gook Shin and Ji-Young Park},
  journal={Clinical pharmacology and therapeutics},
  year={2006},
  volume={80 6},
  pages={646-56}
}
BACKGROUND AND OBJECTIVE 1,4-Dihydropyridine calcium channel blockers, including amlodipine, are mainly metabolized by cytochrome P450 (CYP) 3A. We investigated the effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean male subjects. METHODS Forty healthy male participants were enrolled and genotyped for the CYP3A5*3 gene. Each subject ingested a 5-mg dose of amlodipine, and plasma amlodipine concentrations were measured for 144 hours after… CONTINUE READING